PETALING JAYA: Generic pharmaceutical producers are expected to be best poised to benefit from the deliberated policies relating to the healthcare sector, according to Affin Hwang Capital Research.
However, the research house said organic recovery and the sheer size of an expanded healthcare expenditure should well catalyse the entire sector.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!